Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Stockler

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
The Medical Journal of Australia|October 6, 2001
Hospitalised patients' views on doctors and white coatsB R Gooden, M J Smith, S J Tattersall, et al.
Internal Medicine Journal|June 1, 2012
Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancerG J McCaughan, P L Blinman, M J Boyer, et al.
Breast (Edinburgh, Scotland)|November 10, 2016
More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trialsA Vasista, M R Stockler, T West, et al.
Journal of Clinical Epidemiology|July 3, 1999
Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core Quality of Life QuestionnaireM R Stockler, D Osoba, P Corey, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2012
Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trialsB E Kiely, M Alam, P Blinman, et al.
The Lancet. Oncology|June 3, 2004
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancerA K Nowak, N R C Wilcken, M R Stockler, et al.
Internal Medicine Journal|September 24, 2005
Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancerA M Joshua, I Nordman, R Venkataswaran, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 17, 2016
Phase 1 in the development of a patient-reported measure to quantify perceived inconvenience of radiotherapy: generation of issuesP Sundaresan, C G Milross, M R Stockler, et al.
Internal Medicine Journal|March 12, 2014
Rising cost of anticancer drugs in AustraliaD J Karikios, D Schofield, G Salkeld, et al.
British Journal of Cancer|December 8, 2005
Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?V M Duric, L J Fallowfield, C Saunders, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
The Medical Journal of Australia|October 6, 2001
Hospitalised patients' views on doctors and white coatsB R Gooden, M J Smith, S J Tattersall, et al.
Internal Medicine Journal|June 1, 2012
Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancerG J McCaughan, P L Blinman, M J Boyer, et al.
Breast (Edinburgh, Scotland)|November 10, 2016
More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trialsA Vasista, M R Stockler, T West, et al.
Journal of Clinical Epidemiology|July 3, 1999
Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core Quality of Life QuestionnaireM R Stockler, D Osoba, P Corey, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2012
Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trialsB E Kiely, M Alam, P Blinman, et al.
The Lancet. Oncology|June 3, 2004
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancerA K Nowak, N R C Wilcken, M R Stockler, et al.
Internal Medicine Journal|September 24, 2005
Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancerA M Joshua, I Nordman, R Venkataswaran, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 17, 2016
Phase 1 in the development of a patient-reported measure to quantify perceived inconvenience of radiotherapy: generation of issuesP Sundaresan, C G Milross, M R Stockler, et al.
Internal Medicine Journal|March 12, 2014
Rising cost of anticancer drugs in AustraliaD J Karikios, D Schofield, G Salkeld, et al.
British Journal of Cancer|December 8, 2005
Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?V M Duric, L J Fallowfield, C Saunders, et al.
Pageof 5